One less potential competitor for Botox

|By:, SA News Editor

Johnson and Johnson (JNJ) discontinues its development of PurTox, a neurotoxin intended to compete with Allergan's (AGN) $2B anti-wrinkle blockbuster.

The company acquired the rights to the drug in 2009 with its buy of Mentor Corp.

The move will result in the loss of a small number of U.S.-based jobs.